AI tool predicts Parkinson's progression and medication side effects using a smartwatch
Tests AI models using smartwatch data and health records in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
Key facts
- Where
- Dresden, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07189468, who can take part
Where in Germany
- Technische Universität DresdenDresden, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07189468
- Record updated
- 24 September 2025
- Original description
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.Read full original descriptionShow less
AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.
Inclusion: Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015); Disease duration ranging from 5 to 10 years; Age 40-80; Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition; The participant is using a compatible smartphone; Written informed consent.
Exclusion: Atypical Parkinsonian Syndrome; Second-line device-aided treatments; Patients with >4 daily doses of L-DOPA; Daily levodopa equivalent dose > 1500 mg; Ongoing hallucinations requiring short-term treatment adjustment; Inability to provide informed consent or participate in the study; Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator; Lacking motivation to participate in study procedures - as judged by investigator; Under adult autonomy protection system, legal guardianship or incapacitation; Pregnant and breast-feeding women.